• Home
  • News
  • Calendar
  • About DF/HCC
  • Membership
  • Visitor Center

Roya Khosravi-Far, Ph.D.

Associate Professor, Department of Pathology, Harvard Medical School

Senior Scientist, Experimental Pathology, Beth Israel Deaconess Medical Center

Contact Info

Roya Khosravi-Far
Beth Israel Deaconess Medical Center
330 Brookline Avenue
Boston, MA, 02215
Mailstop: RN 270F
Phone: 617-667-8526
Fax: 617-667-3524


Rajeshwari Bhat
Administrative Assistant
Beth Israel Deaconess Medical Center
330 Brookline Ave
EC/CLS 0634 (Cubicle)
Phone: 617-735-2481
Fax: 617-735-2480

DF/HCC Program Affiliation

Cancer Cell Biology

Research Abstract

One of the major goals of researchers in the field of apoptosis is understanding the molecular mechanisms of the various components of the apoptotic pathways, with the hope to identify targets for novel cancer therapies. However, most cancer cells are resistant to many apoptosis-inducing agents such as most cytokines and radiation. Tumor necrosis factor has been used in some cancer therapies in an effort to eliminate tumor cells, but its administration results in a severe inflammatory response. Similarly, Fas can kill tumor cells but will also cause a sever hepatotoxicity. Recent discovery of a TNF related ligand, TRAIL, that kills transformed cells with great specificity in vitro, has provided further hope that TRAIL may be used to induce cell death in tumor cells without affecting normal tissue. However, the biological function of TRAIL and what pathways are involved in mediating its function is not yet clear. We are currently studying the biological function and tumor specificity of TRAIL-induced killing by analyzing the effect of TRAIL in inhibiting chronic myelogenous leukemia.

Death Receptors (DR) 4 and 5 are activated by TRAIL. The signaling events that mediate the biological effects of TRAIL, DR4 and DR5 are not well characterized. By phage display peptide library screening, we have identified several peptides that directly and specifically interact with DR4 and DR5 receptors. One of the DR5-interacting peptides possesses an inhibitory effect in DR5 and TRAIL-induced cell killing and may provide the mechanism for tumor specificity of TRAIL-induced killing. Identification of pathways that inhibit TRAIL-induced apoptosis in TRAIL-resistant tumor cells will provide valuable targets for cancer therapy. Inhibition of such pathways will convert the TRAIL-resistant tumor cells to TRAIL-sensitive. These cells can then be specifically eliminated by TRAIL-induced apoptosis.


View All Publications